Beam Therapeutics (BEAM) awards 40,000 stock options to Chief Legal Officer

Rhea-AI Filing Summary

Beam Therapeutics Inc. granted Chief Legal Officer Christine Bellon a stock option covering 40,000 shares of common stock. The option has an exercise price of $27.62 per share and expires on January 31, 2036. It was awarded on January 31, 2026 and is held directly.

The option vests in equal monthly installments over 48 months following the grant date, conditioned on Bellon’s continued service with Beam Therapeutics through each vesting date. After this grant, she beneficially owns 40,000 derivative securities in the form of stock options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bellon Christine

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	40,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 40,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bellon Christine

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.62	01/31/2026		A		40,000		(1)	01/31/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

	By: /s/ Christine Bellon	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BEAM report for Christine Bellon?

Beam Therapeutics reported a grant of stock options to Chief Legal Officer Christine Bellon for 40,000 shares of common stock at an exercise price of $27.62 per share, awarded on January 31, 2026 and held as a direct beneficial interest.

How many Beam Therapeutics (BEAM) options were granted in this Form 4?

The Form 4 shows a single grant of 40,000 stock options to Beam Therapeutics’ Chief Legal Officer. These options give the right to buy 40,000 shares of common stock at $27.62 per share, with vesting spread over four years in monthly installments.

What is the exercise price and expiration date of the BEAM options granted?

The stock options granted to Christine Bellon have an exercise price of $27.62 per share and an expiration date of January 31, 2036. This means she can choose to purchase Beam Therapeutics common shares at $27.62 any time before that expiration, subject to vesting.

How do the Beam Therapeutics options granted to Christine Bellon vest?

The options vest in equal monthly installments over 48 months following the January 31, 2026 grant date. Each monthly vesting is conditioned on Christine Bellon’s continued service with Beam Therapeutics through the relevant vesting date, gradually increasing her exercisable option stake.

Is the Beam Therapeutics Form 4 transaction a purchase or a grant?

The Form 4 reflects an option grant, coded as transaction type “A” for acquisition of derivative securities. Beam Therapeutics granted stock options to its Chief Legal Officer, rather than her buying shares on the open market, and the options are exercisable for common stock at $27.62 per share.

Does Christine Bellon hold the Beam Therapeutics options directly or indirectly?

The filing indicates direct ownership of the derivative securities. After the reported grant, Christine Bellon beneficially owns 40,000 stock options directly, with no referenced intermediary entities or footnotes shifting voting or investment authority to another party in this disclosure.